[13 August 2013]
Products Affected - Description
Reason for the Shortage
- Hi-Tech states the shortage was due to manufacturing delays.
- Actavis and GlaxoSmithKline could not provide a reason for the shortage.
- GlaxoSmithKline sold their Zovirax oral presentations to Prestium who launched product in mid-June 2013.
Acyclovir Suspension, Actavis
200 mg/5 mL, 473 mL bottle (NDC 00472-0082-16)
Acyclovir Suspension, Hi-Tech
200 mg/5 mL, 473 mL bottle (NDC 50383-0810-16)
Zovirax Suspension, Prestium
200 mg/5 mL, 473 mL bottle (NDC 00173-0953-96)
Estimated Resupply Dates
- All presentations are available.
August 13, 2013; July 9, 2013; June 18, 2013; May 6, 2013; April 23, 2013; April 9, 2013, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins